Abstract
Background Multiple vaccines against SARS-CoV-2 have been evaluated in clinical trials, but very few include the pediatric population. The inactivated vaccine CoronaVac® has shown to be safe and immunogenic in a phase 1/2 clinical trial in a pediatric cohort in China. This study is an interim safety and immunogenicity report of a phase 3 clinical trial for CoronaVac® in healthy children and adolescents in Chile.
Methods Participants aged 3 to 17 years old received two doses of CoronaVac® in a four-week interval. Local and systemic adverse reactions were registered in 699 participants that received the first dose and 381 that received the second dose until December 31st, 2021. Whole blood samples were collected from 148 participants for humoral and cellular immunity analyses.
Results The primary adverse reaction reported after the first and second dose was pain at the injection site. The adverse reactions observed were primarily mild and local, and no severe adverse events were reported. Four weeks after the second dose, a significant increase in the levels of total and neutralizing antibodies was observed. Increased activation of specific CD4+ T cells was also observed four weeks after the second dose. Although antibodies induced by vaccination neutralize variants Delta and Omicron, titers were lower than the D614G variant. Importantly, comparable T cell responses were detected against these variants of concern.
Conclusions CoronaVac® is safe and immunogenic in subjects aged 3-17 years old and is thus likely to confer protection against infection caused by SARS-CoV-2 variants in this target population.
Competing Interest Statement
XM and QQX are SINOVAC Biotech employees and contributed to the conceptualization of the study and did not participate in the analysis or interpretation of the data presented in the manuscript. A.S. is a consultant for Gritstone, Flow Pharma, Arcturus, Immunoscape, CellCarta, OxfordImmunotech and Avalia. La Jolla Institute for Immunology (LJI) has filed for patent protection for various aspects of T cell epitope and vaccine design work. All other authors declare no conflict of interest.
Clinical Trial
NCT04992260
Funding Statement
The PedCoronaVac03CL Study was funded by SINOVAC Biotech.The National Agency for Research and Development (ANID) through the Fondo Nacional de Desarrollo Cientifico y Tecnologico (FONDECYT) grants No. 1190156, No. 1211547, No.1190830 supports RSR, FVE, and AMK respectively. The Millennium Institute on Immunology and Immunotherapy, ANID-Millennium Science Initiative Program ICN09_016 (former P09/016-F) supports AMK, FVE, KA, LJC, RSR, PAG, and SMB; The Innovation Fund for Competitiveness FIC-R 2017 (BIP Code: 30488811-0) supports ARD, SMB, PAG and AMK. This study was also funded in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93021C00016 to A.S.and Contract No.75N93019C00065 to A.S, D.W.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This report will only focus on the study performed in Chile for participants that received CoronaVac®. In Chile, this trial has been conducted at eleven different sites, eight in the center of the country (seven in Santiago and one in Valparaiso), two in the South (Puerto Montt and Valdivia), and one in the North (Antofagasta) of Chile. The study protocol was conducted according to the current Tripartite Guidelines for Good Clinical Practices, the Declaration of Helsinki 14, and local regulations. This trial was approved by each Institutional Ethical Committee and the Chilean Public Health Institute (ISP Chile, number No. 20674/21). The committee members that reviewed and approved this trial protocol at Pontificia Universidad Católica de Chile (Institutional Scientific Ethical Committee of Health Sciences, Pontificia Universidad Católica de Chile, Approval #210616012) were: Claudia Uribe Torres/President; Colomba Cofré Dougnac/ Executive Secretary; Jorge Muñoz Castillo/External Lawyer;Gustavo Kaltwasser González/ External Member; Alyssa Garay Navea/Community Representative; Marisa Torres Hidalgo/US Department of Public Health; Mónica Cifuentes Soro/External member; Ivonne Vargas Celis/US Bioethics Center; Víctor Contreras/Department of Anesthesiology; Diego García-Huidobro/Department of Family Medicine; Francisco Acevedo/Department of Hemato-Oncology; Ximena Ortega Fuenzalida/Agricultural Engineer, External Member; Mónica Vergara Quezada/Social Worker, Research Ethics and Security Unit.. Website: http://eticayseguridad.uc.cl/comite-etico-cientifico-facultad-de-medicina-uc.html).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵† These authors are coordinators of the PedCoronaVac03CL Study.
Data Availability
All data produced in the present work are contained in the manuscript
